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Background/aim: Right cardiac pathologies develop in patients with obstructive sleep apnea syndrome (OSAS) and in most patients
there are no symptoms in the early stages of right cardiac disorders. We aimed to evaluate a possible relationship between B-type
natriuretic peptide (BNP), blood uric acid, C-reactive protein (CRP), and the right cardiac pathologies in patients with OSAS, and the
role of these parameters in the management of patients with OSAS.
Materials and methods: A total of 98 subjects, 31 (31.6%) controls and 67 (68.4%) with OSAS, were included in the study. All the
subjects underwent polysomnography, and standard and tissue Doppler echocardiography (ECHO) examinations. BNP, CRP, and blood
uric acid levels were measured in all patients.
Results: Upon evaluating the relationship between BNP and ECHO parameters, BNP levels were found to positively correlate with such
ECHO parameters as pulmonary artery pressure. As for the association between CRP and ECHO findings, RV diameter exhibited a
statistically significant positive correlation with them. Moreover, uric acid was found to statistically correlate positively with right atrium
dimensions.
Conclusion: BNP, CRP, and blood uric acid levels can be used as adjunctive parameters in the early diagnosis and follow-up of right
heart pathologies in patients with OSAS.
Key words: OSAS, echocardiography, right cardiac pathologies, BNP, uric acid, CRP

1. Introduction
Obstructive sleep apnea syndrome (OSAS), a syndrome
characterized by partial or total obstruction in the upper
airways, has an incidence of 2%–4% in the population and
it may lead to morbidity and mortality (1,2). Right cardiac
pathologies develop in patients at different rates, and most
patients do not show clinical signs relevant to right cardiac
pathology (3,4). Patients that have clinical symptoms
related to right cardiac pathologies can be diagnosed early
and treated. However, if patients with OSAS who do not
have symptoms associated with right cardiac pathology
could be diagnosed early, the progress of the disease could
be delayed.
Enormous progress has recently been made in
understanding the impact of OSAS on the cardiovascular
system and the associated comorbidities. Although the
exact mechanisms governing these associations are
poorly understood, the accumulated evidence implicates
* Correspondence: dromeraraz@gmail.com
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oxidative stress and inflammation as 2 basic mechanisms
associated with OSAS (5). There is increasing evidence
that intermittent hypoxia plays an important role in the
development of cardiovascular risk in OSAS through
the activation of pulmonary inflammation pathways (6).
It is also known that an increase in sympathetic activity
induced by apnea and hypopnea episodes during the night
may cause systolic and diastolic dysfunction of both right
and left ventricles (7–9). The patient becomes subject to
injuries caused by hypoxia and other events secondary
to hypoxia such as sympathetic discharge during the
episodes and ischemia-reperfusion and production of
reactive oxygen species during reoxygenation (10). The
effect of the events may be evaluated by measuring serum
C-reactive protein (CRP) (11) and blood uric acid levels
(12). Although there are some studies showing increased
CRP levels in OSAS (6), CRP levels correlate well with
adipose tissue mass and obesity rather than OSAS (13).
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CRP levels have been shown to be higher in patients with
OSAS together with cardiovascular diseases compared to
those who have OSAS without cardiovascular diseases
(14). B-type brain natriuretic peptide (BNP) production
from the heart is induced because of the hypoxia and
sympathetic discharge. Elevated BNP levels are associated
with left ventricular hypertrophy, left ventricular diastolic
dysfunction, and impaired functional capacity (15–17).
There is not a sufficient number of studies to predict
clinically asymptomatic right cardiac pathologies in
patients with OSAS. In order to assist with early diagnosis
and understand their role in the management of patients
with OSAS, we aimed to evaluate the possible relationship
between BNP, blood uric acid, CRP, and right cardiac
pathologies in patients with OSAS.
2. Materials and methods
2.1. Study population
A total of 156 OSAS patients and controls were evaluated
between January 2010 and December 2011. Fifty-eight
patients were excluded due to hypertension, chronic
left heart failure, valvular heart disease, coronary artery
disease, pericardial disease, diabetes mellitus, chronic
renal disease, pulmonary disease, a history of smoking
1 pack/year or more, or any infections at the time of the
study or within 2 weeks prior to the study. Additionally,
patients who had left heart pathologies with ECHO were
excluded. A total of 67 consecutive (47 (70.1%) male
and 20 (29.9%) female) patients with OSAS, and 31 (22
(70.9%) male and 9 (29.1%) female) age- and sex-matched
controls were included in the study. Polysomnography was
performed and subjects with an AHI < 5 were defined as
the control group (group 1) while those with AHI ≥ 5 and
excessive daytime sleepiness (EDS) were defined as the
OSAS group (group 2) (18).
2.2. Measurements
After an initial clinical evaluation, a questionnaire
was used to obtain information about snoring history,
witnessed apnea, and EDS. The Epworth Sleepiness Scale
(ESS) was used to evaluate sleepiness. A detailed physical
examination was done and anthropometric measurements,
including neck and waist circumference, height, weight,
and body mass index (BMI), were obtained. Their chest
X-rays, pulmonary function tests, electrocardiograms, and
echocardiograms were also obtained.
Hypertension was defined as an average blood pressure
of ≥140/90 mmHg, according to the National Heart
Lung and Blood Institute criteria, or the current use of
antihypertensive agents. Diabetes mellitus was defined as
a fasting blood glucose level of ≥126 mg/dL. Obesity was
defined as a BMI of ≥25.
A venous blood sample was obtained in the morning
after the completion of PSG. Blood CRP levels (range

0–5 mg/L), blood uric acid levels (range 3.5–7.5 mg/dL),
arterial blood gases, and B-type natriuretic peptide levels
(range 0–100 pg/mL) were measured. Blood uric acid
level was determined by use of a cobas 8000 modular
analyzer series (USA). Blood CRP analysis was conducted
using nephelometry (Database Siemens Germany).
Blood samples were drawn into appropriate tubes for
measurement of BNP levels. BNP analysis was performed
using the fluorescence immunoassay method (Biosite,
San Diego, CA, USA). Arterial blood samples were drawn
from the patients included in the study from the radial
artery, using specially designed heparinized injectors for
arterial blood gas analysis. PaO2, PaCO2, pH, and SaO2
measurements were performed according to the ionselective electrode method via a blood gas analyzer (cobas
b 221, Mannheim, Germany).
2.3. Sleep study
Full PSG monitoring was performed with the Compumedics
E-series Sleep System (Compumedics Sleep, Melbourne,
Australia). Electroencephalography (EEG, C3/A2, C4/
A1, O1/A2, and O2/A1), electrooculography (EOG),
electromyography (EMG), and electrocardiography were
performed simultaneously. Surface electrodes were used to
record EEG channels, right and left EOGs, and submental
EMG. Ventilatory flow, either at the nose or at both the
nose and mouth, was measured with airflow. Respiratory
movements of the chest and abdomen and body position
were monitored by inductive plethysmography bands. The
arterial oxygen saturation was measured transcutaneously
with a finger oximeter. Apnea was defined as a continuous
cessation of airflow for ≥10 s, and hypopnea was defined as
at least a 50% reduction of airflow for ≥10 s with an oxygen
desaturation of ≥3% or an EEG arousal from sleep. Apneas
were classified as obstructive, central, or mixed according
to the standard criteria of the American Academy of Sleep
Medicine (19).
2.4. Echocardiography
All patients underwent conventional 2D and Doppler
echocardiographic investigation in addition to
tissue Doppler imaging by a Vivid 7 (GE, Norway)
echocardiography (ECHO) device using a 2.5 MHz
transducer. In the left lateral decubitus position,
echocardiograms were recorded on standard parasternal
and apical images. The images were viewed and recorded
at end inspiration and end expiration in the patients on
normal ventilation. For each patient, M-mode, B-mode,
color flow mapping, and pulse-wave Doppler records were
obtained.
Left ventricle diastolic diameter (LVDD), left ventricle
systolic diameter (LVSD), left ventricle end diastolic volume
(LVEDV), left ventricle end systolic volume (LVESV),
fractional shortening (FS), left atrium diameter (LA), right
atrium diameter (RA), right ventricle diameter (RV), and
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interventricular septum thickness (IVS) were determined
with a parasternal long-axis view. Left ventricular ejection
fraction (LVEF) was calculated using a modified version
of Simpson’s method (20). Systolic pulmonary arterial
pressure was calculated by adding estimated right atrial
pressure onto the regurgitation gradient through the
tricuspid valve. The dilatation of RA (over 46 mm), RV
(over 45 mm), and elevation of PAP (over 36 mmHg) were
defined as right heart pathologies.
Regarding the standard and tissue Doppler, a pulsed
Doppler evaluation of the left ventricular inflow was
performed by placing the sample volume at the tips of
the mitral valve in apical 4-chamber view. The following
measurements were performed in order to evaluate the
global diastolic functions of the left ventricle: peak E and
A wave velocities (m/s) and E/A ratio; E wave deceleration
time (DT) (ms); isovolumetric relaxation time (IVRT)
(ms) (time period between the end of the systolic flow wave
and the onset of transmitral E wave, which is measured
by placing the pulsed wave sample volume between the
left ventricular outflow tract and the mitral valve). All
the measurements were obtained based on the standard
proposed by the American Echocardiography Society (21).
All patients were informed about the study and
provided their consent to participate. The study was
planned according to the ethics guidelines of the Helsinki
Declaration, and the study protocol was approved by the
local ethics committee (B.30.2.ATA.0.01.00/05).
2.5. Statistical analysis
Data were expressed as mean ± SD and percentage.
Statistical analysis was performed using SPSS for
Windows (Version 19.0; SPSS Inc., Chicago, IL, USA). The
significance of the differences between groups was assessed
using the Kruskal–Wallis test followed by the Bonferronicorrected Mann–Whitney U post hoc test. Spearman’s
correlation analyses were used for ECHO parameters
between BNP, CRP, and blood uric acid. ROC curves of
BNP, CRP, and uric acid were obtained for pulmonary
arterial pressure. The sensitivity, specificity, and positive
and negative predictive values were calculated according
to their upper cut-off values. Statistical significance was
accepted as P values less than 0.05.
3. Results
A total of 98 subjects, 31 (31.6%) controls and 67 (68.4%)
OSAS patients, with a mean age of 49.8 ± 10.9 years and
49.7 ± 12.7 years, were included in the study. Demographic
characteristics and laboratory findings of the groups are
shown in Table 1. PSG and ECHO findings of the groups
are shown in Tables 2 and 3.
BNP was found to show a statistically significant
positive correlation with such ECHO parameters as PAP (P
= 0.03, r = 0.277). As for the association between CRP and
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Table 1. Demographic characteristics of all groups, their
pulmonary function tests, and laboratory findings
Group 1
(n = 31)

Group 2
(n = 67)

P value

Age (years)

49.8 ± 10.9

49.7 ± 12.7

0.032

BMI

29.5 ± 7.3

34.6 ± 8.3

0.037

NC (cm)

36.5 ± 4.2

40.6 ± 4.2

0.012

WC (cm)

98 ± 15.4

111.3 ± 14.6

0.017

ESS

3±2

10 ± 4

0.001

FVC (% pred)

108 ± 13.8

105.7 ± 16.9

0.709

FEV1 (% pred)

103.8 ± 13.6

98.2 ± 17.5

0.381

FEV1/FVC

82.4 ± 6.7

78.1 ± 7.5

0.075

CRP

0.85 ± 0.3

2.87 ± 0.7

0.035

Uric acid

4.1 ± 0.6

9 ± 0.8

0.001

BNP

12.7 ± 4.5

35.8 ± 4.4

0.003

PaO2

76.6 ± 11.3

69.2 ± 7.3

0.880

PaCO2

33.5 ± 4.6

34.3 ± 5.1

0.703

SatO2

95.2 ± 2.7

93.3 ± 4.1

0.805

Data are presented as mean ± SD. BMI: body mass index, NC:
neck circumference WC: waist circumference, ESS: Epworth
sleepiness scale, FVC (% pred): force vital capacity, FEV1 (%
pred): forced expiratory volume in 1 s, FEV1/FVC: forced
expiratory volume in 1 s/forced vital capacity ratio, CRP: C reactive protein, BNP: B - type brain natriuretic peptide, PaO2:
partial pressure of oxygen, PaCO2: partial pressure of carbon
dioxide SatO2: oxygen saturation.
Table 2. Cardiorespiratory polysomnography results of all groups
Group 1
(n = 31)

Group 2
(n = 67)

P value

AHI

1.5 ± 1.4

52.6 ± 32.3

0.001

MD

4.3 ± 2.5

8.1 ± 4.9

0.002

DT90

26.7 ± 53

118.7 ± 98.3

0.001

MOD

84 ± 10.5

70.9 ± 4.9

0.002

AHT

1.98 ± 2.4

29.3 ± 13.8

0.001

MAHR

171.5 ± 58

200.8 ± 70.2

0.378

MHR

66.9 ± 8.2

75.6 ± 11.4

0.013

LHR

22.6 ± 17.3

19.1 ± 9.4

0.795

Data are presented as mean ± SD. AHI: apnea-hypopnea index,
MD: mean desaturation, DT90: desaturation time under 90
(min), MOD: maximum oxygen desaturation, AHT: apneahypopnea time (min), MHR: mean heart rate, LHR: lowest heart
rate, MAHR: maximum heart rate.
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Table 3. Echocardiographic measurements of all groups.
Group 1
(n = 31)

Group 2
(n = 67)

P value

LVDD (mm)

45.6 ± 4.1

46.9 ± 4.7

0.310

LVSD (mm)

27.8 ± 3.8

29.3 ± 4.5

0.367

LVEDV (mm)

92.8 ± 8.8

96.6 ± 21.7

0.263

LVESV (mm)

60.2 ± 11.5

60.8 ± 16.4

0.745

FS (%)

36.8 ± 4.2

37.6 ± 5.7

0.494

LA (mm)

36 ± 2.6

37.1 ± 3.1

0.344

RA (mm)

36 ± 2.9

48.1 ± 5.3

0.269

RV (mm)

35.7 ± 2.5

48.9 ± 5.6

0.010

IVS (mm)

9.8 ± 1.4

10.8 ± 1.2

0.039

PAP

25.3 ± 7.5

41.2 ± 12.9

0.012

DT (ms)

184.3 ± 26.4

180 ± 37.7

0.499

IVRT (ms)

81.5 ± 7.3

82.1 ± 6.6

0.676

E/A ratio

1.02 ± 0.2

0.99 ± 0.1

0.623

LVEF (%)

63.3 ± 3.2

64.2 ± 4.1

0.017

Data are presented as mean ± SD. LVDD: left ventricle diastolic
diameter, LVSD: left ventricle systolic diameter, LVEDV: left
ventricle end diastole volume, LVESV: left ventricle end systole
volume, FS: fractional shortening, LA: left atrium diameter,
RA: right atrium diameter, RV: right ventricle diameter, IVS:
interventricular septum, PAP: pulmonary artery pressure DT:
mitral deceleration time IVRT: isovolumic relaxation time, E/A:
ratio of early and lately mitral flow velocity, LVEF: left ventricular
ejection fraction.

ECHO findings, the RV diameter exhibited a statistically
significant positive correlation with them (P = 0.004, r
= 0.322). Uric acid levels were positively correlated with
ECHO findings like RA diameter (P = 0.006, r = 0.310).
All 3 parameters (BNP, CRP, and blood uric acid) were
documented to have a statistically significant relationship
with AHI ((P = 0.002, r = 0.350), (P = 0.032, r = 0.242), (P
= 0.001, r = 0.441), respectively).
When adjusted for age and BMI, in particular, the
statistically significant correlation between PAP and BNP

was observed to persist. In the present study a statistically
significant correlation between BNP level and all the
ECHO parameters indicates the involvement of the left
heart, except for LVEDV. The age- and BMI-adjusted levels
of BNP, CRP, and blood uric acid, and ECHO right heart
findings are presented in Tables 4 and 5.
ROC curves of BNP, CRP, and uric acid obtained for
pulmonary arterial pressure are shown in Figures 1a–1c.
The sensitivity, specificity, and positive and negative
predictive values calculated according to their upper cutoff values are summarized in Table 6.
4. Discussion
Right cardiac pathologies are detected in different rates in
OSAS patients (3,4) and there are frequently no clinical
symptoms. Blood BNP, uric acid, and CRP levels can be
of predictive value for right cardiac pathologies in patients
with OSAS.
Primary pulmonary changes due to chronic
intermittent hypoxia and apnea arousals, besides many
coexisting factors, such as obesity, systemic hypertension,
and coronary artery disease, may cause deterioration in the
RV in patients with OSAS (22). Most studies reported that
concomitant chronic pulmonary disorders were required
for OSAS to cause RV dysfunction. Severe impairment
of pulmonary hemodynamics occurs in patients with
concomitant lung disease and morbid obesity. However,
the pulmonary hemodynamics is also likely to be disrupted
on the sole basis of hypoxia and sympathetic discharge
induced by OSAS, without coexistent pulmonary disease
and other problems (3,23,24). Accordingly, PAP was found
to be elevated in our patients with OSAS (group 2) despite
the absence of additional disease. However, BMI was
higher in OSAS patients than it was in the control group.
In various conditions, including left cardiac disorders
and many others out of the left cardiac disorders, BNP
can increase. Fernandez Fabrellas et al. reported in their
study a relationship between BNP and echocardiographic
parameters like increased ventricular septal thickness, left
ventricular posterior wall thickness, or left ventricular
end-diastolic diameter (25). Arias et al. also reported a

Table 4. Echocardiographic measurements with BNP, CRP, and blood uric acid between correlations adjusted to age.
Group 1

Group 2

CRP (P/r)

BUA (P/r)

BNP (P/r)

CRP (P/r)

BUA (P/r)

BNP (P/r)

RA

(0.001/–0.185)

(0.001/–0.545)

(0.001/–0.283)

(0.02/0.360)

(0.001/0.308)

(0.001/0.371)

RV

(0.308/0.048)

(0.001/–0.564)

(0.510/0.031)

(0.001/0.104)

(0.001/0.180)

(0.001/0.152)

PAP

(0.008/–0.147)

(0.001/0.250)

(0.001/–0.448)

(0.001/0.275)

(0.001/0.457)

(0.001/0.251)

RA (mm): right atrium diameter, RV (mm): right ventricle diameter, PAP (mmHg): pulmonary artery pressure, CRP: C - reactive
protein, BNP: B - type brain natriuretic peptide, BUA: blood uric acid.
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Table 5. Echocardiographic measurements with BNP, CRP, and blood uric acid between correlations adjusted to BMI.
Group 1

Group 2

CRP (P/r)

BUA (P/r)

BNP (P/r)

CRP (P/r)

BUA (P/r)

BNP (P/r)

RA

(0.001/–0.215)

(0.001/–0.483)

(0.001/–0.297)

(0.009/0.050)

(0.001/0.318)

(0.001/0.271)

RV

(0.466/0.041)

(0.001/–0.484)

(0.652/0.025)

(0.001/0.134)

(0.001/0.190)

(0.001/0.174)

PAP

(0.001/–0.204)

(0.001/–0.460)

(0.001/–0.452)

(0.001/0.253)

(0.001/0.236)

(0.001/0.238)

1.0

1.0

0.8

0.8

0.6

0.6
Sensitivity

Sensitivity

RA (mm): right atrium diameter, RV (mm): right ventricle diameter, PAP (mmHg): pulmonary artery pressure, CRP: C - reactive
protein, BNP: B - type brain natriuretic peptide, BUA: blood uric acid.

0.4

0.2

0.2

0.0

0.4

0.0

0.2

0.4

0.6

0.8

1.0

0.0

0.0

0.2

0.4

0.6

0.8

1.0

1 - Specificity

1 - Specificity

1.0

0.8

Sensitivity

0.6

0.4

0.2

0.0

0.0

0.2

0.4

0.6

0.8

1.0

1 - Specificity

Figure 1a. ROC curves of B - type brain natriuretic peptide for pulmonary artery pressure. b. ROC curves of C - reactive
protein for pulmonary artery pressure. c. ROC curves of blood uric acid for pulmonary artery pressure.
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Table 6. The sensitivity, specificity, and positive and negative predictive values calculated according to
their upper cut-off values.
AUC

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

BNP

0.589

16.7

98.2

66.7

84.4

CRP

0.509

8.3

98.2

50

83.4

Uric acid

0.603

0

96.4

0

81.5

AUC: area under the curve, PPV: positive predictive value, NPV: negative predictive value, BNP: B-type
brain natriuretic peptide, CRP: C - reactive protein.

correlation between PAP and the severity of the disease
in the presence of LV diastolic dysfunction (26). In the
present study we documented a statistically significant
correlation between BNP levels and all the ECHO
parameters indicating the involvement of the left heart,
except for LVEDV. Our study documented a positive
correlation between the severity of OSAS and BNP levels.
Although the former study reported a weak relationship
between the left ventricle and BNP, we found a prominent
relationship between BNP and age-adjusted parameters
indicative of left ventricle functions and morphology. In
addition to acting as an indicator of left heart involvement,
BNP level was found in our study to have a statistically
significant positive correlation with right cardiac functions
and morphology. We find it remarkable that a robust
correlation existed between elevation in PAP and BNP
level, especially in the patients in group 2.
It is known that increases in CRP level in OSAS patients
were due to increased inflammation. CRP is documented
to be one of the proinflammatory proteins and an elevated
CRP level is an important risk factor in atherosclerosis
(27). However, a rise in CRP levels has been shown to

be significant in patients with OSAS with cardiovascular
diseases compared to those who have OSAS without
cardiovascular diseases (14). We showed that high CRP
levels are correlated with asymptomatic right cardiac
pathologies in OSAS patients as well as in those with other
cardiovascular diseases.
Each airway obstruction episode inducing hypoxemia
causes episodes of ischemia-reperfusion injury. Such
damage has mainly been attributed to the generation of
reactive oxygen species during reoxygenation (28). This
damage causes increased blood uric acid levels and uric
acid excretion (29,30). Increased hypoxemia affects PAP
and the right heart (31). Consequently, blood uric acid
level, which is an indicator of hypoxemia, can be used to
anticipate right cardiac pathologies in OSAS patients. Our
study revealed statistically positive correlations between
uric acid levels and right cardiac echo parameters. Uric
acid levels in the blood may provide an idea regarding
right cardiac echo parameters.
In conclusion, BNP, CRP, and blood uric acid levels can
be used as adjunctive parameters in the early diagnosis and
follow-up of right heart pathologies in patients with OSAS.
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